Medullary Thyroid Carcinoma
Biology, management, and treatment of sporadic and hereditary MTC
2., Second Edition 2025
Springer Nature Switzerland
ISBN 978-3-031-80396-3
Standardpreis
Bibliografische Daten
eBook. PDF
2., Second Edition 2025. 2025
XVI, 307 p. 48 illus., 30 illus. in color..
In englischer Sprache
Umfang: 307 S.
Verlag: Springer Nature Switzerland
ISBN: 978-3-031-80396-3
Weiterführende bibliografische Daten
Das Werk ist Teil der Reihe: Recent Results in Cancer Research
Produktbeschreibung
After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists.
Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC.
This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
Autorinnen und Autoren
Produktsicherheit
Hersteller
Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg, DE
ProductSafety@springernature.com